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Abstract Epithelial-mesenchymal-transition (EMT) tumor-
igenesis in the mouse was first described over 100 years
ago using various terms such as carcinosarcoma and
without any comprehension of the underlying mechanisms.
Such tumors have been considered artifacts of transplanta-
tion and of tissue culture. Recently, EMT tumors have been
recognized in mammary glands of genetically engineered
mice. This review provides a historical perspective leading
to the current status in the context of some of the key
molecular biology. The biology of mouse mammary EMT
tumorigenesis is discussed with comparisons to human
breast cancer.
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Abbreviations
EMT epithelial-mesenchymal-transition
MET mesenchymal-epithelial-transition
K cytokeratin
CK cytokeratin
IHC immunohistochemistry
SMA smooth muscle actin
Erα estrogen receptor alpha
GEM genetically engineered mice
EMT and Neoplastic Progression: Lessons
from the Mouse
As is frequently the case in breast cancer research, much of
the fundamental biology begins with the mouse. In fact,
what are now called EMT tumors were first described as
carcinosarcomas in the mouse mammary tumor literature of
the early 1990’s[ 1, 2]. The first report of a mouse
mammary tumor using microscopic examination, in 1854,
concludes that the tumor was “scirrhous” [3]. This
descriptive term implies “hard” but may have had a
different meaning in the 1850s. Livinggood, who described
and illustrated five mouse mammary tumors in 1896, felt
obliged to comment that they were not sarcomas as
believed by others [4]. The terminology in that era was a
bit of a slippery slope. For example, the authoritative
opinion of the times was that the mouse tumors were
“Familiare Endotheliome” (Family Endotheliomas) [5].
This interpretation was probably based on Virchow and
Connheim’s “Blastema” hypothesis that all cancers arose
from embryonic rests in the connective tissue coupled with
a misinterpretation of the microacinar pattern as being
endothelial lining [2]. This debate was finally closed
20 years later [6].
Some of the earliest microscopic illustrations of mouse
mammarycancersincludedspindlecell“carcinosarcomas”[1,
7, 8]. Apolant’s classic descriptions of mouse mammary
tumors in 1906 included carcinosarcomas with a drawing of
a spindle cell tumor in chapter D. entitled “Die Entwickelung
des Sarkomas auf dem Boden transplantierter Carci-
nome.” (The development of sarcomas from primary
transplanted carcinomas.”)[ 1]( F i g .1a). Apolant described
transplantation experiments with tumors as “Sarkom mit
Carcinomrest” [1]. His later paper, with Paul Ehrlich,
illustrates a tumor with a combination of glands and spindle
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DOI 10.1007/s10911-010-9184-ycells [9]. Haaland, who provided the first descriptive
classification of mouse mammary tumors in English in
1911, discusses carcinosarcomas [8]. Woglom, in a massive
1913 review of the extant scientific literature, defended the
then prevalent view that carcinosarcomas were primarily
artifacts of transplantation [6].
The context of these observations needs to be under-
stood. In 1882, alcohol was the major “hardening” agent
and formalin is not on the list [10]. Formaldehyde did not
become generally available until 1896 [11]. Livinggood
stated that he used alcohol fixation [4]. However, celloiden
and paraffin sectioning were available and microtomes
produced relatively thin sections. By 1913 Mallory pro-
vides recipes for almost all of the stains used today [12].
Perhaps, the major limitation was in the available micro-
scopes and photographic equipment to document observa-
tions. However, the artwork available provides impressively
accurate artistic reproductions [13]. Later, many of the early
papers were clearly illustrated using camera lucida [8].
Of course, inbred mice were not yet available during this
early era in breast cancer research and transplant histocom-
patibility was unknown. Mice were usually purchased from
mouse fanciers and animal husbandry practices were
somewhat poor to non-existent. In 1913, Mallory’s section
on mice recommends that mice be kept in glass cages with
holes for air, be bedded in cotton balls and be fed bread and
cheese [12]. Round worm infestations were prevalent,
leading Borell and others to speculate that mouse mammary
cancers were caused by round worms [14, 15].
However, some investigators kept detailed transplant
records and found that some tumors could be maintained in
serial transplantation within families of mice [16]. Jensen
developed the first mouse mammary tumor transplant line
which could be maintained in serial section [17]. The
Figure 1 Historical. Figure 1
depicts copies of illustrations
of mammary “Spindelzollensar-
kom” from Apolant 1907 (a)
“carcinosarcoma” from Dunn
1945 (b), mouse mammary
“EMT-type” tumor with immu-
nohistochemical stains for cyto-
keratin 8/18 (c) and smooth
muscle actin (d) from White et
al.[ 47] 2001 and a “triple
negative” human breast cancer
with undifferentiated cells that
stain for vimentin (e) and cyto-
keratin 8/18 (f). Apolant associ-
ated his spindle cell and mixed
tumors with transplantation [1].
Dunn associated her mixed
tumor with tissue culture and
explantation [23]. White found
spontaneous EMT-type tumors
with loss of the ILK1 transgene
and up regulation of Snail [47].
The dual staining, triple
negative phenotype in human
breast cancer is not recognized
as a specific subset or with a
specific diagnostic term.
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Jensen for his discovery was vigorously, and somewhat
rudely, contested by Williams who considered Jensen’s
work artifactual [17, 18]. Before discounting the work of
these early pioneers, the reader is encouraged, at a
minimum, to read the table of contents to the 1911 report
of the Imperial Cancer Fund [19]. The pioneers were
quintessential natural historians. They asked the right
questions while laying the foundations of experimental
mammary cancer biology [2, 20].
In 1913, Tyzzer and his graduate student C.C. Little, the
founder of The Roscoe B. Jackson Memorial Laboratory
(JAX), set out to develop inbred strains of mice for the
purpose of studying the genetic basis for breast cancer [21].
The inbred laboratory mouse became the primary experi-
mental model in cancer research and led to, amongst many
other biologically significant observations, the discovery of
histocompatibility antigens [2]. The 1920s and 1930s saw
the development of numerous strains of mice inbred for
various traits. Biochemistry and tissue culture were devel-
oped and added to our scientific tool box. By 1945 Thelma
Dunn was able to survey an extensive literature on the
pathology of mouse mammary tumors and provided a new
classification of mouse mammary tumors that included
carcinosarcomas (Fig. 1b). Her conclusion was that carci-
nosarcomas were primarily artifacts of tissue culture [22,
23]. This effectively ended any debate about mouse
mammary carcinosarcomas. The rare spindle cell tumors
occurring spontaneously were subsequently ignored or
attributed to newly discovered sarcoma viruses.
The Interim
However, those pesky spindle cells did not disappear.
Attempts to develop mouse mammary cell lines met with
great difficulty. Most cell cultures became “fibroblastic”
and were “sarcomatous” upon transplantation. In the 1960s
and 1970s investigators devised techniques to rid the
cultures of “fibroblasts” [24]. Occasionally, investigators
were able to develop sustainable epithelial mouse mammary
cell lines [25, 26]. For example, a method was developed
for maintaining primary cultures in low passage using high
density cultures and light trypsinization to limit growth of
“fibroblasts” [24]. Using time-lapse cinematography,
Young et al. demonstrated that the epithelial cells in these
“dome cultures” divided into two types of daughter cells.
One daughter cell became an epithelial cell while the
second daughter migrated to the periphery of the dome to
become a “fibroblastic” spindle cell.
In 1989, a series of experiments using vectors carrying the
H-Ras gene, Strange et al. found that unrestricted transfec-
tion led to undifferentiated spindle cell tumors while
transfection with a single copy of H-Ras resulted in an
epithelial tumor [27]. These experiments performed in the
“modern era” were, in retrospect, clues about the plasticity
of mouse mammary cells and the role of oncogenes.
During this time, as is well documented in this issue,
developmental biologists were discussing epithelial-
mesenchymal-transition. In 1989, Thiery’s observations
with malignant tranformation in tissue culture introduced
the concept of epithelial-mesenchymal-transition (EMT)
tumors [28]. Thiery found that EMT was associated with
SRC (SRC sarcoma oncogene) and FGF (fibroblast growth
factor) [28–30]. While the concept had impact in the
experimental pathology community, it had little or no
impact or serious discussion in the diagnostic community.
The major emphasis within the tumor biology commu-
nity has been on the events inside tumors and host-tumor
interactions [28, 31]. The work of Condeelis and others has
provided dramatic and convincing evidence of EMT within
epithelial cancers. Condeelis and Pollard demonstrated,
using in-vivo microscopy, that EMT-type of transitions
occur in Tg(MMTV:PyVmT) mouse mammary tumors on
the level of a single tumor cell [32–36]. These tumor cells
“break away” from their adjacent tumor cells and are
escorted along collagen fibers by tumor-associated macro-
phages (TAM) to blood vessels. Cellular analysis of these
cells by Condeelis has detailed the structural and molecular
changes occurring in these migratory cells [33]. The synergic
co-migration of TAM and invading breast cancer cells can be
explained by a direct paracrine loop by which carcinoma
cells secrete specific macrophage growth factors (i.e. CSF-1
(colony-stimulating factor-1)), that, in turn, activate macro-
phages to secrete epithelial growth factors and chemokines
(i.e. EGF(epidermal growth factor), HGF (hepatocyte growth
factor), SDF-1 (stromal cell-derived factor-1)) responsible
for stimulating carcinoma cell invasion and intravasation
[33, 35, 37]. The crosstalk between TAM and tumor cells
also affects the activity of actin regulators, such as WASP
(Wiskott–Aldrich syndrome protein), resulting in the gener-
ation of the fundamental migratory and invasive “tools” in
macrophages and invadopodia in tumor cells [33, 38].
Thompson’s 2007 review article on EMT tumorigenesis
elicited sharp replies from the clinical community [39, 40].
Thompson and others envision the type of intratumoral
EMT event documented by Condeelis. Tarin took the
viewpoint that EMT had never been observed in human
breast cancer [39]. One could argue that the two opinions
were separated by experiences in experimental biology and
clinical pathology. The author of the current review took an
intermediate view based on his experiences in experimental
and surgical pathology [41]. Namely, the clinical practici-
oners had not looked with the proper tools. The rest of this
review will recount the evidence from genetically engi-
neered mouse models.
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In 1984, murine breast cancer biology was turned upside
down by the introduction of genetic engineering [42]. In vivo
experimental genomics now became a reality. Suddenly,
specific genes could be cloned and inserted behind
mammary-specific promotors to produce gene-specific
tumor phenotypes [43, 44] and pathway specific pheno-
types [43, 44]. Conversely, knocking out tumor suppressor
genes led to heterogeneous tumor types that could be
attributed to the initiating oncogene [45]. The p53 null
mice developed numerous types of cancers including
mammary cancers [46]. About50%ofthemammarycancers
from these knock-out mice were “spindle cell” tumors and
classified as “fibrosarcomas” or “angiosarcomas”. When
mammary-specific conditional knock-outs continued to pro-
duce heterogeneous tumors with unknown initiating onco-
genes [45], the “occasional” spindle cell component was
ignored or under-reported.
For us, the first real clue about these pesky, but rare,
spindle cells occurred in 2001 when White reported
mammary tumors induced in Tg(Ilk-1) (integrin-linked
kinase) mice had a long latency, incomplete penetrance
and lost of expression of the initiating oncogenic transgene
[47] (Fig. 1c, d). These tumors all had a spindle cell
component mixed with dysplastic glands. They over-
expressed the Snail transcription factor associated with
epithelial-mesenchymal-transition [47]. The speculation, at
that time, was that these were the E-M Transitions first
described in cultured tumor cells by Thiery et al. in 1989
[29, 30]. Later, spindle cell tumors were also found within
populations of persistent and recurrent doxycycline-induced
tumors [48]. Some of the inducible mouse lines produced
more spindle cell tumors than others. Further analysis
showed these spindle cell tumors to be associated with loss
of p53 [49]. Since the original observations in GEM
mammary tumors, an increasing number of examples have
come to light in a wide variety of mouse models [48–58].
The EMT Type Tumor
Yes, these types of spindle cell tumors of the mammary
gland have been around for a long time. What is new, is that
the investigator now has immunohistochemistry to docu-
ment that the spindle cell population in these “mixed
tumors” expresses epithelial (Fig. 2) and mesenchymal
markers (Fig. 3). We also have mechanistic explanations for
the spindle cell phenotype. As we learn more about how
phenotypes reflect molecules, our classifications should
include molecular mechanisms. Thus, EMT type tumor
becomes a synonym for carcinosarcoma and includes
spindle cell populations that are only recognized using
immunohistochemistry and molecular analysis. Spindle cell
tumors appear as primary mammary tumors in some
genetically engineered mice with a loss of the expression
of the initiating oncogenes or escape from oncogene
addiction [33, 36, 59, 60]. Although EMT tumorigenesis
is emperically linked with the loss of oncogene expression,
the mechanisms are unknown. At the present time, the
transition to mesenchymal phenotypes appears yet another
mechanism creating tumor plasticity.
These phenomena required reconsideration of EMT
tumorigenesis as a process and as a diagnostic category
[47, 48, 54, 61]. These tumors were initially categorized
as “spindle-cell” tumors but subsequent immunohisto-
chemical analysis demonstrated the presence of CKs,
vimentin and SMA. These molecules suggest a mixed
lineage or a myoepithelial cell origin [54]. Some cohorts
have up-regulation of the Snail transcription factor
associated with other types of EMT [48]. Others have
mutations in p53. These attributes justified the application
of the term “EMT” to these tumor types. Dual staining
with epithelial (cytokeratin) and mesenchymal (vimentin)
biomarkers is a reliable diagnostic criterion [51]. But dual
staining should not exclude non-staining tumors.
Epithelial Origin
Since most of the GEM tumors arose in animals with
epithelial-specific targeted transgenes or silenced tumor
suppressor genes, the tumors likely arose from the
mammary epithelium. Direct experimental evidence of
epithelial origin comes from tumors derived directly from
Figure 2 Spindle cell tumor. Figure 2 illustrates the expression of
cytokeratin 8/18 detected by immunocytochemistry. Note that the
epithelial clusters have the most intense staining pattern. Futhermore,
the spindle cell population of fusiform cells with polar cytoplasm also
expresses the epithelial antigen. Compare this pattern with staining
patterns in Figs. 1 and 3.
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Another spindle cell phenotype tumor arose directly from
cultured epithelial cells after in vivo transfection with a
Snail construct [48]. Remember that “carcinosarcomas”
were regarded by early investigators as artifacts of
transplantation and tissue culture. These experiments are
reminiscent of these early observations but provide some
mechanistic proof.
Studies in GEM demonstrate that spindle cell tumors
arising from the mammary epithelium, in spite of the diverse
initial oncogenic stimuli, have a common morphological
end-point. While the spindle cell populations dominate these
tumor types, they have a range of epithelial phenotypes.
Some populations have no epithelial clusters. Others have
small clusters of epithelial cells. Some tumors retain very
distinct epithelial populations with minor dual staining
populations. These cohorts illustrate the range of possibilities
in the EMT phenotype in the mouse mammary gland.
Immunohistochemistry studies demonstrated that dual
staining for the two intermediate filaments, vimentin and
CKs, staining for SMA and a loss of E-Cadherin staining
are common immunophenotypes in most spindle cell
tumors in all cohorts thus far studied. Simultaneous
immunohistochemical staining of representative samples
demonstrated colocalization of the two intermediate fila-
ments in the same fusiform cells. Thus, immunohistochem-
istry provides convenient, reliable and specific criteria for
EMT-phenotype in mouse mammary tumors. The retention
of IHC staining epithelial biomarkers also suggests reten-
tion of epithelial characteristics.
We have recommended that the diagnosis of EMT tumor
be restricted to those tumors whose biological and
Figure 3 Heterogeneity.
This panel illustrates some types
of heterogeneity found in EMT
tumorigenesis. Panels a and b
show a subcutaneous EMT
tumor from a Tm(p53±xHas±)
female. a is stained with hema-
toxylin and eosin illustrating the
spindle cell morphology of
EMT tumors. b is stained using
immunohistochemistry (IHC)
for Cytokeratin 8/18 demon-
strating that the spindle cells are
uniformly postive of K8/18.
The rectangle shown in the
thumbnail overviews indicate
the approximate area viewed
in the high magnification.
Compare this pattern with the
IHC patterns in the Tg(Myc)-
associated EMT tumor in panels
C-F. c is stained for K8/18, d for
Vimentin, e K14 and f for
Smooth Muscle Actin (SMA).
Different areas in the tumor
have differential staining for
each antigen. For example, the
densest SMA stain is at the
upper tip of the upper sample (f)
but K14 staining is more intense
around this area (e). This tumor
has many tumor giant cells that
are lacking in a and b. The scale
bar (d) indicates 50 μm magni-
fication of all the higher magni-
fication images. Compare these
patterns with the cover illustra-
tion that shows well-defined
nests of epithelial cells in a sea
of spindle cells.
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staining cells [51, 57]. The variants that appear within EMT
cohorts or of unknown origin should be considered EMT-
Type tumors until definitive proof of lineage is provided.
EMT-Type Tumor Heterogeneity
The supposition that any spindle cell population originates
from epithelium can be challenged. Not all spindle cell
tumors in the mouse mammary glands are “EMT Type
Tumors”. Other tumor types may have a spindle cell
phenotype but are not dual staining [51]. The spindle cell
tumors associated with splenic myeloid hyperplasia and
dermal sarcomas are an example [63]. Pure sarcomas do
exist and may appear in the mammary fat pad. As
documented above, some EMT Type Tumors do not
express dual biomarkers [51]. Other EMT tumors will vary
in the intensity of antigenic staining from region to region
(Figs. 1, 2 and 3). Thus, a dilemma occurs when tumors
resemble the spindle cell tumors of epithelial origins but do
not stain for intermediate filaments. The diagnosis in these
cases resides in the molecular phenotype as discussed below.
As intimated above, the usual dual-staining spindle cell
tumor from the mouse mammary gland has a mixture of
gland-like structures, tumor giant cells and dominant spindle
cell populations (comparethe tumorsinFigs. 1, 2 and 3). The
amount of and differentiation of, the pure epithelial
component varies. In some cases, “epithelial” differentiation
can only be identified with IHC stains for keratins (See
Fig. 3a, b). In other cases, “almost normal” epithelial ducts
are present. It is not always clear whether these well
differentiated structures are entrapped normal host or a part
of the neoplastic population. In some extreme examples, a
large, if not major, component of the tumor is clearly
epithelial, thus creating the appearance of a “collision”
tumor. The variation of tumors within any given experimen-
tal cohort demonstrates the heterogeneity (Fig. 3c–f).
The observation of great heterogeneity, within the same
cohort and the same tumor, raises the possibility that not all
of the spindle cell tumors are the result of EMT. For
example, they could arise from mesenchymal subpopula-
tions and be mixed cell populations or bi-phasic tumors.
The demonstration that two intermediate filaments colocal-
ized in the same cells supports the hypothesis that they
arose from the same lineage but does not exclude the
possibility of fusion of two cell types or recruitment from
other cell populations such as a putative stem cell. For the
time being, it seems reasonable to assume that dual staining
in spindle cell populations is evidence of an epithelial-
mesenchymal-transition. However, in most cases, one is
limited to observation of the terminal events without
rigorous experimental evidence of origins [51].
Common and Rare Phenotypes Associated with EMT
As indicated in the historical review, spindle cell tumors
have been observed in the mammary glands of laboratory
mice for more than a century. They are frequently observed
in the context of transplantation and explants from tissue
culture. As discussed above they are also seen in the
context of genetic engineered mice. Now that we have
specific criteria for the recognition of EMT tumorigenesis,
one wonders whether such tumors occur in other previously
overlooked situations. Sixty-four ageing wild type FVB/N
females were studied to establish the prevalence and
phenotype of spontaneous mammary and pituitary tumors
[56]. Of fourteen mammary tumors, five mice with pituitary
tumors had mammary masses consistent with EMT-
phenotype tumors. They all showed immunohistochemical
expression of CK8/18, vimentin and SMA.
The rare and unexpected observation was that ERα-
expression in these EMT-phenotype tumors was observed
in the cytoplasm [56]. A retrospective analysis of selected
mouse mammary EMT tumors from all of the EMT cohorts
previously analyzed also showed cytoplasmic expression of
ERα. A marked ERα nuclear expression without cytoplas-
Figure 4 Biology. This panel illustrates the expansile, pushing
margin between tumor and host that generally occurs in mouse
mammary tumors (a) (image captured at 4×). Compare image 4Awith
the typical infiltrating margin of an spindle cell EMT-type tumor (b)
which infiltrates between the fat cells in the field depicted rather than
pushing and compressing the host apidocytes (scale bar is 100 um).
Both images depict Tg(Neu) tumors. Image 4A is a Neu-induced
primary tumor. Image 4B is a recurrent tumor in a doxycycline-
induced Neu host.
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glandular structures suggesting that cytoplasmic ERα is
closely related to the EMT phenotype. These empirical
observations illustrate an association but do not distinguish
between cause and effect. However, anyone with experi-
ence with human breast cancer will testify that cytoplasmic
staining for ER is frequently observed and rigorously
ignored. Is this another one of those phenomena ignored
until validated in the mouse [41]?
EMT Tumor Biology
EMT has been consistently associated with poor prog-
nosis in human tumors. The Epithelial to Mesenchymal
Transition has been suggested as one of the mechanisms
that allowed primary tumors to invade and colonize other
tissue, forming metastases and giving a poorer progno-
ses. In human breast cancer, Snail is being used as a
surrogate biomarker for EMT. Over expression of Snail,
a transcriptional repressor, has been associated with an
increased incidence of metastases in human literature
[64]. The Condeelis and Pollard experiments are consis-
tent with this notion because they demonstrate that
macrophages are recruited into Tg(PyVmT) tumors and
“escort” individual tumor epithelial cells to vascular
spaces and into the circulation as metastatic cells.
However, mouse EMT tumors, with increased expression
of Snail and it’s downstream pathway, are associated with
decreased metastases [51, 53]. Further, the spindle cell
tumors from other cohorts, although more locally
invasive, have had no documented metastases (Fig. 4).
In fact, metastatic cells in most mouse models travel to the
lungs via intravascular tumor emboli composed of clusters
of epithelial cells [45, 65, 66]. Lungs with a combination
of micrometastases and tumor emboli may demonstrate
that both mechanisms can contribute to the metastatic
phenotype.
The EMT tumors of mouse mammary glands are locally
aggressive, invading local tissues and growing through
fascia and muscles. Thus far, we have not observed a single
distant metastasis from spontaneous or tissue culture
explants. However, tail vein injections of spindle cell
tumors will colonize the mouse lungs. Therefore, while
EMT is associated with more aggressive types of neoplasia
in humans, the same is not true in mice.
Several hypotheses can explain the different biological
behaviors. The most obvious is that the mouse is not
human and the same phenomena could have different
species-related outcomes. While a tempting explanation,
it is not a testable hypothesis. One testable hypothesis
would be that the spindle cell tumors of the mouse are a
biological dead-end with terminal differentiation. The
terminal differentiation is not metastatic. This hypothesis
would suggest that tumors we see in mice have lost the
plasticity required for EMT and its reciprocal, MET.
Perhaps, if human EMT tumors could be encouraged to
terminally differentiate, their populations would not
metastasize.
What constitutes EMT Tumorigenesis? Does such a
tumor type exist in human breast cancer [39, 40, 67]? The
current status of the field leaves us with diagnostic and
biological dilemmas. In the clinical arena, reports of EMT
in human tumors are based largely on expression micro-
arrays emphasizing the loss of expression of “epithelial”
genes such as e-Cadherin and up-regulation of genes
associated with mesenchymal differentiation (Snail, Twist
and Slug). Images of the histopathology show disorganized
epithelial tumors that do not have the spindle cell
differentiation found in the mouse tumors [68]T h e s e
observations raise the question of appropriate diagnostic
criteria of “EMT” tumors. What are the limits of EMT?
Does a range of tumors, such as found in the mouse, exist
that fit one or more criteria for EMT? Or, should the
diagnostic use of the term be limited only to tumors that
have all of the criteria? Are we justified in categorizing
breast tumors on the basis of their expression microarrays?
A huge literature now exists that sorts human breast cancer
using expression microarrays or immunohistochemistry to
correlate certain expression patterns with clinical outcome
[69, 70].
As in the past, the biology of neoplasia might be better
understood from the perspective of the mouse. If the
observation in GEM is correct and universal, EMT
tumorigenesis involves the loss of expression of the
initiating oncogene with concomitent silencing of the entire
oncogenic pathway. What are the mechanisms that trigger
this dramatic change in oncogenic stratigies? Is the
phenomena epigenetic as implied by the MET (mesenchy-
mal-epithelial-transition) implied by the morphology of the
metastaic foci [39, 40]. We have postulated here that the
spindle cell phenotype that is so characteristic of the mouse
EMT tumors, is an end point in the neoplastic progression.
If so, the intermediate stages need to be identified. Again
the mechanistic implications of each stage need definition.
By any criteria, the emerging data correlating over
expression of mesenchymal and EMT transcription markers
with poor prognosis demands our attention. Our diagnostic
and therapuetic approaches will be based on a better
understanding of the origins and mechanisms of EMT
tumorigenesis.
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